Clinical Trial

A Single-arm, Prospective Phase Ⅱ Clinical Study of Utidelone Combined with Capecitabine in the Treatment of Active Brain Metastasis of TNBC

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated September 19, 2024 (before its estimated June 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This study aims to explore the efficacy and safety of the combination therapy of utidelone and capecitabine in the treatment of brain metastases from triple-negative advanced breast cancer, and to search for systemic treatment for brain metastases from triple-negative advanced breast cancer cases.
Trial Details
NCT Number NCT06598046
Lead Sponsor Henan Cancer Hospital
Conditions Metastatic Breast Cancer
Enrollment 48 participants
Start Date 2024-06-19
Primary Completion 2026-06-01 (estimated)
Study Completion 2026-08-01 (estimated)
Updated on ClinicalTrials.gov 2024-09-19